Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Saper, Joel
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine Enrollment initiated in combination with Emgality for episodic migraine Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine	Completed	4	580	US	Galcanezumab, LY2951742, Rimegepant, Placebo	Eli Lilly and Company	Migraine, Episodic Migraine	05/23	05/23
NCT05207865: Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention	Active, not recruiting	4	208	US	Rimegepant, BHV-3000	Pfizer	Migraine, Episodic Migraine, Phonophobia, Photophobia	07/24	07/24
Babcock, Jill
No trials found
Majestic, Jennifer
No trials found
Szalay, Shawn
No trials found
Weintraub, James
No trials found
Sculli, Lauren
No trials found